Shots:

• The P-II TAURIEL study involves assessing of semorinemab vs PBO in 457 patients with early AD across 97 sites
• Genentech divulges that the P-II TAURIEL study did not meet its co-1EPs of efficacy (reducing decline on CDR-SB) but meets its 1EPs of safety while the two 2EPs (ADAS-Cog13 & ADCS-ADL) was not met- results will be presented at the upcoming medical congress
• The second P-II LAURIET study of semorinemab in patients with moderate AD remains ongoing. Additionally- IND enabling studies are ongoing for first-in-class therapeutic candidates targeting TDP-43 and alpha-synuclein

­ Ref: PRNewswire | Image: Fortune